Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease

被引:2
作者
Porth, Rachel [1 ]
Deyhim, Tina [1 ]
Geeganage, Grace [1 ]
Smith, Brenden [1 ]
Zullow, Samantha [1 ]
Rabinowitz, Loren G. [1 ]
Grossberg, Laurie B. [1 ]
Cheifetz, Adam S. [1 ]
Papamichael, Konstantinos [1 ]
机构
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Div Gastroenterol, Boston, MA 02115 USA
关键词
Crohn's disease; ulcerative colitis; proactive therapeutic drug monitoring; ustekinumab; reactive therapeutic drug monitoring;
D O I
10.1093/ibd/izae231
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: There are limited data on the role of proactive therapeutic drug monitoring (TDM) of ustekinumab (UST) in patients with inflammatory bowel disease (IBD). This study investigated the efficacy and safety of proactive TDM in IBD patients treated with subcutaneous (sc) UST. Methods: This was a retrospective single-center cohort study. Consecutive patients with IBD who received maintenance subcutaneous (sc) UST therapy and underwent TDM from January 2017 to February 2023 were eligible for inclusion. Patients were followed through May 2024 or until drug discontinuation or an IBD-related surgery. Patients underwent either at least one proactive TDM or reactive TDM only. Survival analysis was performed to evaluate drug persistence, defined as no need for drug discontinuation due to loss of response, serious adverse event (SAE) or an IBD-related surgery, and IBD-related hospitalizations. Results: The study population consisted of 83 patients (proactive TDM, n = 46) of whom 67 (81%) had Crohn's disease. Patients who had at least one proactive TDM had higher drug persistence (Log-rank P < .001) and less IBD-related hospitalization (Log-rank P = .012) compared to patients undergoing only reactive TDM. In multivariable COX proportional hazard regression analysis, at least one proactive TDM was associated with increased drug persistence (hazard ratio [HR]: 5; 95% confidence interval [95% CI], 2-10; P < .001) and decreased IBD-related hospitalization (HR: 0.24; 95% CI, 0.07-0.83; P = .024). There was no SAE reported. Conclusions: This retrospective study showed that proactive TDM is associated with increased drug persistence and decreased IBD-related hospitalization in IBD patients treated with sc UST. Lay Summary There is still limited information regarding the role of therapeutic drug monitoring (TDM) other than antitumor necrosis factor biologics. This study showed that proactive TDM is associated with increased drug persistence and decreased inflammatory bowel disease (IBD)-related hospitalization in patients with IBD treated with ustekinumab.
引用
收藏
页码:1806 / 1810
页数:5
相关论文
共 50 条
[41]   Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease [J].
Brian Bressler ;
Jennifer Jones ;
Tracy S. H. In ;
Tommy Lan ;
Cristian Iconaru ;
John K. Marshall .
Advances in Therapy, 2023, 40 :4421-4439
[42]   Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease [J].
Bressler, Brian ;
Jones, Jennifer ;
In, Tracy S. H. ;
Lan, Tommy ;
Iconaru, Cristian ;
Marshall, John K. .
ADVANCES IN THERAPY, 2023, 40 (10) :4421-4439
[43]   Therapeutic Drug Monitoring in Inflammatory Bowel Disease History and Future Directions [J].
Spencer, Elizabeth A. ;
Dubinsky, Marla C. .
PEDIATRIC CLINICS OF NORTH AMERICA, 2017, 64 (06) :1309-+
[44]   Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease [J].
Detrez, Iris ;
Van Stappen, Thomas ;
Martin Arranz, Maria D. ;
Papamichael, Kostas ;
Gils, Ann .
THERAPEUTIC DRUG MONITORING, 2017, 39 (04) :344-349
[45]   Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease [J].
McNeill, Richard P. ;
Barclay, Murray L. .
CURRENT OPINION IN PHARMACOLOGY, 2020, 55 :41-46
[46]   Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases [J].
Gonczi, Lorant ;
Kurti, Zsuzsanna ;
Rutka, Mariann ;
Vegh, Zsuzsanna ;
Farkas, Klaudia ;
Lovasz, Barbara D. ;
Golovics, Petra A. ;
Gecse, Krisztina B. ;
Szalay, Balazs ;
Molnar, Tamas ;
Lakatos, Peter L. .
BMC GASTROENTEROLOGY, 2017, 17
[47]   New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease [J].
Khan, Afrasyab ;
Berahmana, Arvenia B. ;
Day, Andrew S. ;
Barclay, Murray L. ;
Schultz, Michael .
NEW ZEALAND MEDICAL JOURNAL, 2019, 132 (1491) :46-62
[48]   Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review [J].
Frank I. Scott ;
Gary R. Lichtenstein .
Current Treatment Options in Gastroenterology, 2016, 14 (1) :91-102
[49]   Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions [J].
Ward, Mark G. ;
Sparrow, Miles P. ;
Roblin, Xavier .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
[50]   Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study [J].
Paul, Stephane ;
Del Tedesco, Emilie ;
Marotte, Hubert ;
Rinaudo-Gaujous, Melanie ;
Moreau, Amelie ;
Phelip, Jean-Marc ;
Genin, Christian ;
Peyrin-Biroulet, Laurent ;
Roblin, Xavier .
INFLAMMATORY BOWEL DISEASES, 2013, 19 (12) :2568-2576